VALNEVA Stock Drops 2.71% at Close Following Zika Vaccine Rebound
After a strong performance on Tuesday due to positive news about its Zika virus vaccine candidate, VALNEVA has declined at the end of Wednesday, November 5th. The stock fell by 2.71% to 3.87 euros, affected by profit-taking amid extremely compressed trading. This volatility contrasts with the stability of the Paris market, where the CAC 40 remains almost unchanged.
At the close of this Wednesday, November 5th, VALNEVA's share price stood at 3.87 euros, down 2.71% from the previous close of 3.98 euros. This movement comes after a particularly strong session on Tuesday, during which the stock had jumped by 3.23% to 4.02 euros, making it the top performer of the SBF 120 index at mid-session. Trading volumes remain very limited, with only 0.23% of capital traded, reflecting the restricted liquidity characteristic of small biotech values. Over the year, VALNEVA has nonetheless shown solid performance with a gain of 46.7%, significantly outperforming the CAC 40 which has recorded a 9.53% increase. This relative outperformance highlights the attractiveness of the biotechnology sector in 2025. Over the last three months, the stock has increased by 20.34%, while over the past week, it has seen a limited decline of 0.77%, reflecting the stock's extreme responsiveness to announcements and the speculative nature inherent in healthcare stocks.
Weakness on Wednesday Following a Major Announcement
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
Almost there! Check your inbox.
A confirmation email has been sent. Click the link to confirm your subscription.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Wednesday's weakness follows a significant announcement made on Tuesday: Valneva announced positive Phase 1 results for its VLA1601 Zika virus vaccine candidate, indicating an improved immune response with a double adjuvant. This announcement had energized investors on Tuesday, leading to a significant rebound in the stock price before the correction occurred. The observed pattern suggests opportunistic profit-taking after Tuesday's rise, a common phenomenon in low-liquidity stocks where reactions to announcements tend to be amplified in both directions. Technically, the stock shows mixed signals that do not clearly decide. The RSI at 24 indicates an oversold condition, while the Stochastic suggests a potential buy signal. The stock is currently trading between its 50-day moving average (4.19 euros) and 200-day moving average (3.38 euros), remaining above the latter and confirming an underlying bullish structure. Bollinger Bands frame the price between 4.77 euros (upper resistance) and 3.70 euros (lower limit), with the stock positioned close to its lower boundary. The MACD shows a moderate divergence between its line (?0.14) and its signal line (?0.11), reflecting a slight loss of upward momentum without a marked bearish signal.
Au troisième trimestre, nous avons continué à nous concentrer sur le renforcement de notre trésorerie, ce qui nous a permis de refinancer notre dette à des conditions financières plus avantageuses.
Chiffre d’affaires de 127,0 millions d’euros sur neuf mois (+8,9 %), ventes de 119,4 millions d’euros, trésorerie de 143,5 millions d’euros au 30/09/2025, perte nette 65,2 millions d’euros, EBITDA ajusté (37,7) millions d’euros. Guidance 2025 confirmée : chiffre d’affaires attendu entre 165 et 180 millions d’euros; ventes attendues entre 155 et 170 millions d'euros. Renforcement de la position financière via refinancement et ATMs; Phase 3 VALOR pour le vaccin Lyme en cours selon calendrier.
Risks mentioned
Suspension de la licence IXCHIQ ® aux États-Unis par la FDA (impact sur ventes segment voyageurs)
Risque de résultats cliniques défavorables pour les candidats (phase 3 VALOR pour Lyme, essais S4V2, VLA1601 incertitudes réglementaires)
Exposition aux fluctuations de change (impact négatif mentionné de 1,3 millions d’euros sur ventes, effets de change volontaires)
Dépendance à des partenaires de distribution et diminution des produits de tiers (arrêt de distribution de Rabipur/RabAvert et Encepur)
Opportunities identified
Résultats positifs potentiels de la Phase 3 VALOR (VLA15) pouvant mener à des demandes d'autorisation en 2026
Accord commercial avec CSL Seqirus en Allemagne pour stimuler la commercialisation des vaccins
Croissance des ventes d'IXCHIQ ® sur les marchés hors États-Unis et dans les PRFI (livraisons de substance active)
Potentiel du candidat S4V2 contre la shigellose (marché estimé > 500 millions de dollars/an)
Données positives de Phase 1 pour VLA1601 (Zika) et forte persistance d'anticorps pour IXCHIQ ® (95 % à 4 ans) comme avantage concurrentiel
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
